Title

Authors

Affiliation

¹Department of IT, GITAM University,Patancheru Mandal,Medak Dist-502329; ²Pydah College of Engineering and Technology, Gambheeram, Anandapuram (M); Visakhapatnam-531163; ³Jawaharlal Nehru Technological University Kakinada, Kakinada, Andhra Pradesh-533003

Email

susmitagv@gmail.com; *Corresponding author

Article Type

Hypothesis

Date

Received December 05, 2013; Accepted December 19, 2013; Published December 27, 2013

Diabetic Retinopathy (DR) is one of the attenuating complications of diabetes mellitus. The key gene responsible for causing diabetic retinopathy is protein kinase C beta (PKCβ). Protein kinase C is a family of protein kinase enzymes which are involved in controlling the function of other proteins through phosphorylation mechanism and plays a crucial role in signal transduction mechanisms. Among all the PKC isoenzymes, PKCβ could be a significant isoenzyme involved in vascular dysfunction during hyperglycemia. Studies show that oral administration of PKCβ inhibitor Ruboxistaurin (LY333531), decreases vessel permeability and improves retinal condition. Thus compounds that decrease the PKCβ activation would be helpful in the treatment of diabetic retinopathy. The compounds similar to Ruboxistaurin are taken from Super Target database and docking analysis was performed. Maleimide derivative 3 showed highest binding affinities compared to Ruboxistaurin and so we advise that compound may be utilized in the treatment of diabetic retinopathy.

Keywords

PKCβ, Ruboxistaurin, Diacylglycerol (DAG), Diabetic retinopathy (DR).

Citation

Gogula et al. Bioinformation 9(20): 1040-1043 (2013)

Edited by

P Kangueane

ISSN

0973-2063

Publisher

Biomedical Informatics

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.